NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 322,800 shares, a drop of 51.3% from the September 30th total of 663,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.4% of the shares of the stock are short sold.

NBY remained flat at $$0.61 during trading on Monday. 189,900 shares of the company’s stock were exchanged, compared to its average volume of 1,125,317. NovaBay Pharmaceuticals has a twelve month low of $0.23 and a twelve month high of $4.04. The business’s 50-day simple moving average is $0.68 and its two-hundred day simple moving average is $1.02.

Separately, LADENBURG THALM/SH SH assumed coverage on shares of NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They set a “buy” rating and a $1.10 price objective for the company.

An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Jane Street Group LLC acquired a new stake in shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 37,287 shares of the biopharmaceutical company’s stock, valued at approximately $63,000. Jane Street Group LLC owned approximately 0.18% of NovaBay Pharmaceuticals at the end of the most recent reporting period.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Read More: Why are analyst ratings important in trading stocks?

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.